Elise Sverre

  • Consultant; MD, PhD
  • +47 990 20 329

Date of birth: 6. March 1979. Civil status: Married, one child. Nationality: Norwegian 
Phone: +47 99020329 Email: elisbj@vestreviken.no 
Home page NORCOR research group: https://norcor.no

Education

  • MD, University of Oslo, 2006
  • PhD, University of Oslo, 2015-2018
  • Specialist in Internal Medicine (2016)

Work record

  • Trainee in cardiology, Oslo University Hospital, Ullevål (2022-current)
  • Post-doctoral fellow Dept. of Medicine, Drammen Hospital (2018-2022)
  • Acting consultant in cardiology, Drammen Hospital (2011-2022)
  • Resident, Internal Medicine and Cardiology, Drammen Hospital (2007-2011)

Memberships and other

  • Professional member European Society of Cardiology (ESC), European Association for Preventive Cardiology (EAPC), Norwegian Society of Cardiology 
  • Co-chair of the NORCOR research group
  • Teacher in clinical communication, University of Oslo (2019-2020)

Research areas

  • Preventive cardiology
  • Clinical pharmacology
  • Cardiac intervention studies
  • Behavioural medicine
 

Publications 2024

Atar D, Munkhaugen J, Sverre E (2024)
Statin discontinuation: How can we improve on the multiple pathways that contribute to suboptimal statin adherence?
Kardiol Pol (in press)
DOI 10.33963/v.phj.102335, PubMed 39240921

Engebretsen I, Bugge C, Støvring H, Husebye E, Sverre E, Dammen T, Halvorsen S, Munkhaugen J (2024)
Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event
Atherosclerosis, 393, 117550
DOI 10.1016/j.atherosclerosis.2024.117550, PubMed 38657552

Lauritzen T, Munkhaugen J, Bergan S, Sverre E, Peersen K, Lindahl S, Husebye E, Vethe NT (2024)
Mevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease
Clin Transl Sci, 17 (10), e70025
DOI 10.1111/cts.70025, PubMed 39444168

Pivoriunas J, Vethe NT, Husebye E, Fagerland MW, Bergan S, Kristiansen O, Munkhaugen J, Sverre E (2024)
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy
Eur Heart J Cardiovasc Pharmacother, 10 (4), 307-315
DOI 10.1093/ehjcvp/pvae001, PubMed 38196131

Pleym K, Dammen T, Wedon-Fekjaer H, Husebye E, Sverre E, Tonstad S, Munkhaugen J (2024)
A multi-component intervention increased access to smoking cessation treatment after hospitalization for atherosclerotic cardiovascular disease: a randomized trial
Eur Heart J Open, 4 (2), oeae028
DOI 10.1093/ehjopen/oeae028, PubMed 38666249

Publications 2023

Dammen T, Munkhaugen J, Sverre E, Moum T, Papageorgiou C (2023)
Psychiatric disorders, rumination, and metacognitions in patients with type D personality and coronary heart disease
Nord J Psychiatry, 77 (6), 540-546
DOI 10.1080/08039488.2023.2182358, PubMed 37079379

Frøjd LA, Munkhaugen J, Papageorgiou C, Sverre E, Moum T, Dammen T (2023)
Predictors of health-related quality of life in outpatients with coronary heart disease
Front Psychol, 14, 1119093
DOI 10.3389/fpsyg.2023.1119093, PubMed 37359852

Lauritzen T, Munkhaugen J, Peersen K, Kristiansen O, Sverre E, Nebauer SD, Villseth M, Andersen AM, Svarstad AC, Jensen EP, Bergan S, Husebye E, Vethe NT (2023)
Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms
Clin Pharmacol Ther, 113 (4), 887-895
DOI 10.1002/cpt.2844, PubMed 36622792

Munkhaugen J, Sverre E, Dammen T, Husebye E, Gjertsen E, Kristiansen O, Aune E (2023)
Frailty, health literacy and self-care in patients admitted with acute heart failure
Tidsskr Nor Laegeforen, 143 (17)
DOI 10.4045/tidsskr.23.0297, PubMed 37987080

Sverre E, Halvorsen S, Løchen ML, Munkhaugen J (2023)
[E. Sverre et al. respond]
Tidsskr Nor Laegeforen, 143 (3)
DOI 10.4045/tidsskr.23.0062, PubMed 36811436

Publications 2022

Frøjd LA, Dammen T, Munkhaugen J, Weedon-Fekjær H, Nordhus IH, Papageorgiou C, Sverre E (2022)
Insomnia as a predictor of recurrent cardiovascular events in patients with coronary heart disease
Sleep Adv, 3 (1), zpac007
DOI 10.1093/sleepadvances/zpac007, PubMed 37193392

Frøjd LA, Papageorgiou C, Munkhaugen J, Moum T, Sverre E, Nordhus IH, Dammen T (2022)
Worry and rumination predict insomnia in patients with coronary heart disease: a cross-sectional study with long-term follow-up
J Clin Sleep Med, 18 (3), 779-787
DOI 10.5664/jcsm.9712, PubMed 34633284

Munkhaugen J, Kristiansen O, Sverre E, Retterstøl K, Tonstad S (2022)
Statins seldom cause adverse reactions
Tidsskr Nor Laegeforen, 142 (2)
DOI 10.4045/tidsskr.21.0885, PubMed 35107944

Sverre E, Halvorsen S, Løchen ML, Munkhaugen J (2022)
Personalised cardiovascular disease prevention in the new guidelines
Tidsskr Nor Laegeforen, 142 (17)
DOI 10.4045/tidsskr.22.0508, PubMed 36416647

Sverre E, Peersen K, Kristiansen O, Fagerland MW, Perk J, Husebye E, Vethe NT, Dammen T, Munkhaugen J (2022)
Tailored clinical management after blinded statin challenge improved the lipid control in coronary patients with self-perceived muscle side effects
J Intern Med, 291 (6), 891-893
DOI 10.1111/joim.13454, PubMed 35103360

Publications 2021

Frøjd LA, Munkhaugen J, Moum T, Sverre E, Nordhus IH, Papageorgiou C, Dammen T (2021)
Insomnia in patients with coronary heart disease: prevalence and correlates
J Clin Sleep Med, 17 (5), 931-938
DOI 10.5664/jcsm.9082, PubMed 33399066

Kristiansen O, Sverre E, Peersen K, Fagerland MW, Gjertsen E, Gullestad L, Perk J, Dammen T, Husebye E, Vethe NT, Munkhaugen J (2021)
The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease
Atherosclerosis, 336, 23-29
DOI 10.1016/j.atherosclerosis.2021.09.020, PubMed 34610521

Kristiansen O, Vethe NT, Peersen K, Wang Fagerland M, Sverre E, Prunés Jensen E, Lindberg M, Gjertsen E, Gullestad L, Perk J, Dammen T, Bergan S, Husebye E, Otterstad JE, Munkhaugen J (2021)
Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial
Eur Heart J Cardiovasc Pharmacother, 7 (6), 507-516
DOI 10.1093/ehjcvp/pvaa076, PubMed 32609361

Munkhaugen J, Sverre E, Peersen K, Kristiansen O, Gjertsen E, Gullestad L, Erik Otterstad J (2021)
Is the novel LDL-cholesterol goal <1.4 mmol/L achievable without a PCSK9 inhibitor in a chronic coronary population from clinical practice?
Eur J Prev Cardiol, 28 (8), e10-e11
DOI 10.1177/2047487320923187, PubMed 33611511

Peersen K, Munkhaugen J, Olsen SJ, Otterstad JE, Sverre E (2021)
Post-myocardial infarction rehabilitation and secondary prevention in hospitals
Tidsskr Nor Laegeforen, 141 (16)
DOI 10.4045/tidsskr.21.0349, PubMed 34758605

Peersen K, Munkhaugen J, Otterstad JE, Olsen SJ, Sverre E (2021)
Post-myocardial infarction rehabilitation and secondary prevention in hospitals
Tidsskr. Nor. Laegeforen., 141 (16), 1523-1526

Peersen K, Munkhaugen J, Sverre E, Kristiansen O, Fagerland M, Vethe NT, Perk J, Husebye E, Dammen T (2021)
Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects
BMC Cardiovasc Disord, 21 (1), 596
DOI 10.1186/s12872-021-02422-7, PubMed 34915854

Publications 2020

Peersen K, Otterstad JE, Sverre E, Perk J, Gullestad L, Moum T, Dammen T, Munkhaugen J (2020)
Medical and Psychosocial Factors Associated With Low Physical Activity and Increasing Exercise Level After a Coronary Event
J Cardiopulm Rehabil Prev, 40 (1), 35-40
DOI 10.1097/HCR.0000000000000399, PubMed 30720643

Publications 2018

Munkhaugen J, Peersen K, Sverre E, Gjertsen E, Gullestad L, Dammen T, Husebye E, Otterstad JE (2018)
The follow-up after myocardial infarction - is it good enough?
Tidsskr Nor Laegeforen, 138 (5)
DOI 10.4045/tidsskr.17.1050, PubMed 29513442

Munkhaugen J, Peersen K, Sverre E, Gjertsen E, Gullestad L, Dammen T, Husebye E, Otterstad JE (2018)
The follow-up after myocardial infarction- is it good enough?
Tidsskr. Nor. Laegeforen., 138 (5), 434-437

Publications 2017

Munkhaugen J, Sverre E, Otterstad JE, Peersen K, Gjertsen E, Perk J, Gullestad L, Moum T, Dammen T, Husebye E (2017)
Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients
Eur J Prev Cardiol, 24 (9), 981-989
DOI 10.1177/2047487317693134, PubMed 28196429

Sverre E, Otterstad JE, Gjertsen E, Gullestad L, Husebye E, Dammen T, Moum T, Munkhaugen J (2017)
Medical and sociodemographic factors predict persistent smoking after coronary events
BMC Cardiovasc Disord, 17 (1), 241
DOI 10.1186/s12872-017-0676-1, PubMed 28877684

Sverre E, Peersen K, Husebye E, Gjertsen E, Gullestad L, Moum T, Otterstad JE, Dammen T, Munkhaugen J (2017)
Unfavourable risk factor control after coronary events in routine clinical practice
BMC Cardiovasc Disord, 17 (1), 40
DOI 10.1186/s12872-016-0387-z, PubMed 28109259

Sverre E, Peersen K, Otterstad JE, Gullestad L, Perk J, Gjertsen E, Moum T, Husebye E, Dammen T, Munkhaugen J (2017)
Optimal blood pressure control after coronary events: the challenge remains
J Am Soc Hypertens, 11 (12), 823-830
DOI 10.1016/j.jash.2017.10.007, PubMed 29128603

Publications 2016

Munkhaugen J, Sverre E, Peersen K, Egge Ø, Gjertsen Eikeseth C, Gjertsen E, Gullestad L, Erik Otterstad J, Husebye E, Dammen T (2016)
Patient characteristics and risk factors of participants and non-participants in the NOR-COR study
Scand Cardiovasc J, 50 (5-6), 317-322
DOI 10.1080/14017431.2016.1202445, PubMed 27323914

Publications 2015

Munkhaugen J, Sverre E, Peersen K, Gjertsen E, Gullestad L, Moum T, Otterstad JE, Perk J, Husebye E, Dammen T (2015)
The role of medical and psychosocial factors for unfavourable coronary risk factor control
Scand Cardiovasc J, 50 (1), 1-8
DOI 10.3109/14017431.2015.1111408, PubMed 26488672